Compugen (CGEN) to Collaborate with Bayer Schering on Compugen Discovered Oncology Target
Compugen Ltd. (NASDAQ: CGEN) announced today that they have signed a collaboration agreement with Bayer Schering Pharma AG, Germany covering the further evaluation of a Compugen discovered tumor target and its splice variants.
The existence of the target and its splice variants was initially predicted in silico by Compugen through the use of its Monoclonal Antibody (mAb) Targets Discovery Platform; the predicted molecules were then validated experimentally.
The agreement provides Bayer with an option for an exclusive worldwide royalty bearing license for development of monoclonal antibodies and other therapeutic agents addressing these novel target molecules.
The existence of the target and its splice variants was initially predicted in silico by Compugen through the use of its Monoclonal Antibody (mAb) Targets Discovery Platform; the predicted molecules were then validated experimentally.
The existence of the target and its splice variants was initially predicted in silico by Compugen through the use of its Monoclonal Antibody (mAb) Targets Discovery Platform; the predicted molecules were then validated experimentally.
The agreement provides Bayer with an option for an exclusive worldwide royalty bearing license for development of monoclonal antibodies and other therapeutic agents addressing these novel target molecules.
The existence of the target and its splice variants was initially predicted in silico by Compugen through the use of its Monoclonal Antibody (mAb) Targets Discovery Platform; the predicted molecules were then validated experimentally.
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Apricus Biosciences (APRI) Granted Request for MycoVa Type C Regulatory Guidance from FDA
- Medivation (MDVN) Submits NDA for Enzalutamide to U.S. FDA
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
